Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06097676 · ClinicalTrials.gov registry record · Phase 4
An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users
A Phase 4 study, sponsored by Arbor Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
NCT06097676: Completed Phase 4 study, sponsored by Arbor Pharmaceuticals.
NCT06097676 is a Phase 4 study that has completed, run by Arbor Pharmaceuticals. The registered enrollment target is 86 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06097676, a Phase 4 study, has completed, sponsored by Arbor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the abuse potential of gabapentin enacarbil in healthy adult, non-dependent, recreational drug users.
Primary Outcome
Mean difference in Drug Liking Emax over 24 hours for Drug Liking ("At this moment, my liking for this drug is"), assessed on a bipolar (0 to 100 points; 0: Strong disliking, 50: Neither like nor dislike, 100: Strong liking) VAS.
Interventions
- DRUG Placebo
- DRUG Alprazolam 2 mg
- DRUG Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg
- DRUG Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg
- DRUG Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 4 |
What the finished NCT06097676 record still lists
NCT06097676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT06097676 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06097676 about?
NCT06097676 is a clinical study titled "An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users". The purpose of this study is to assess the abuse potential of gabapentin enacarbil in healthy adult, non-dependent, recreational drug users.
What is the current status of trial NCT06097676?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2021-09-28. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT06097676?
The interventions under investigation include: Placebo (DRUG), Alprazolam 2 mg (DRUG), Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg (DRUG), Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg (DRUG), Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg (DRUG).
Who is sponsoring clinical trial NCT06097676?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06097676's enrollment target sits among peer trials
86 926th of 2000 higher than 1,073 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI